Allos Therapeutics to Hold Post Advisory Committee Conference Call.WESTMINSTER, Colo. -- Allos Therapeutics, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :ALTH) today announced the Company will hold a webcast conference call on Wednesday, September 2, 2009 to discuss the outcome of the U.S. Food and Drug Administration's (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) Oncologic Drugs Advisory Committee meeting for FOLOTYN[TM] (pralatrexate). FOLOTYN is the Company's investigational selective antifolate that is currently being evaluated by the FDA for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma T-cell lymphoma A malignant proliferation of T cells arising in the skin, diagnosed by detecting rearrangement of the T-cell receptor's β chain; TCLs are often 'driven' by EBV and other viral infections; 90% of all Pts with TCL have extracutaneous involvement . Time: 5:30 pm ET / 4:30 pm CT / 3:30 pm MT / 2:30 pm PT Date: September 2, 2009 Dial-in: 877-941-6009 (U.S. and Canada) or +1-480-629-9771 (international). Webcast: To access the live audio webcast or the subsequent archived recording, visit the "Investors - Presentations and Events" section of the Allos website at www.allos.com. Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call. Callers can access the replay by dialing 800-406-7325 (domestic) or +1-303-590-3030 (international). The passcode is 4151544#. The webcast will be recorded and available for replay on the Company's website until September Until September is a 1984 romantic drama set in France. It stars Karen Allen as an American tourist in Paris who falls in love with a married Frenchman (Thierry Lhermitte). External links 11, 2009. About Allos Therapeutics Allos Therapeutics, Inc. (Nasdaq:ALTH) is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. The Company's product candidate, FOLOTYN[TM] (pralatrexate), is a selective antifolate designed to accumulate preferentially in cancer cells. In May 2009, the FDA accepted the Company's NDA (Non Disclosure Agreement) An agreement signed between two parties that have to disclose confidential information to each other in order to do business. In general, the NDA states why the information is being divulged and stipulates that it cannot be used for any for pralatrexate for the treatment of patients with relapsed or refractory PTCL PTCL Pakistan Telecommunication Company Limited PTCL Peripheral T Cell Lymphoma PTCL Physical and Theoretical Chemistry Laboratory PTCL Pakistan Tobacco Company Limited for priority review and established a Prescription Drug User Fee Act The Prescription Drug User Fee Act (PDUFA) was a law passed by the United States Congress in 1992 which allowed the Food and Drug Administration (FDA) to collect fees from drug manufacturers to fund the new drug approval process. date of September 24, 2009 for a decision regarding approval of the NDA. In addition, FOLOTYN is being evaluated in other tumor types, including solid tumors and a range of lymphoma sub-types. Allos retains exclusive worldwide rights to FOLOTYN for all indications. The Company is headquartered in Westminster, CO. For additional information, please visit www.allos.com. The Allos logo is a trademark of Allos Therapeutics, Inc. |
|
|||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion